SpyGlass Ophthalmics, a privately-held ophthalmic therapeutics company, has secured $27.5 million in Series B financing. The financing was led by Vensana Capital alongside existing investor New Enterprise Associates.

SpyGlass Ophthalmics was Co-founded by Dr. Malik Y. Kahook, MD and Glenn Sussman. The company is focused on the development of novel treatments for chronic ophthalmic diseases. The technology was originally developed in the Sue Anschutz-Rodgers Eye Center of the University of Colorado School of Medicine and spun off campus post Series A funding from New Enterprise Associates.